Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Corcept Therapeutics (CORT) EBIT (2016 - 2025)

Corcept Therapeutics' EBIT history spans 10 years, with the latest figure at $4.5 million for Q4 2025.

  • For Q4 2025, EBIT fell 82.24% year-over-year to $4.5 million; the TTM value through Dec 2025 reached $44.8 million, down 67.29%, while the annual FY2025 figure was $44.8 million, 67.29% down from the prior year.
  • EBIT for Q4 2025 was $4.5 million at Corcept Therapeutics, down from $10.2 million in the prior quarter.
  • Across five years, EBIT topped out at $46.6 million in Q3 2024 and bottomed at $3.4 million in Q1 2025.
  • The 5-year median for EBIT is $29.5 million (2023), against an average of $26.3 million.
  • The largest annual shift saw EBIT soared 98.61% in 2024 before it plummeted 88.42% in 2025.
  • A 5-year view of EBIT shows it stood at $36.7 million in 2021, then tumbled by 38.63% to $22.5 million in 2022, then soared by 40.76% to $31.7 million in 2023, then dropped by 20.23% to $25.3 million in 2024, then tumbled by 82.24% to $4.5 million in 2025.
  • Per Business Quant, the three most recent readings for CORT's EBIT are $4.5 million (Q4 2025), $10.2 million (Q3 2025), and $26.7 million (Q2 2025).